Clinical trials: Asthmatic Patients
Severe Uncontrolled Asthma
Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma
This pilot study will use novel technologies to collect information about the patient experience before and early after starting Fasenra (benralizumab) as standard of care for severe uncontrolled asthma in a real-world setting…
- Trial name
- TWINKLE (NCT04200326)
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Asthma
Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients
The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide using a Gamma-scintigraphic technique after inhalation of a single…
- Trial name
- NCT02975843
- Testing
- Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy and Safety Study of 610 in Patients With Severe Asthma
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
- Trial name
- NCT06323213
- Testing
- 610
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma
The purpose of this study is to determine whether a single IV dose of N6022 will have a significant bronchoprotective effect, compared with placebo, during methacholine challenge.
- Trial name
- NCT01316315
- Testing
- Active
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Nivalis Therapeutics, Inc.
Asthma (Diagnosis), Pulmonary Function
Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)
This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation.
- Conditions
- Asthma (Diagnosis), Pulmonary Function, Moderate-to-Severe Asthma
- Trial name
- syMMPonia (NCT07191535)
- Testing
- linvemastat
- Volunteers
- 135 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Allergic Asthma
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
This study will establish a clinical data and serum repository of anaphylaxis cases associated with Xolair administration and control patients who have received Xolair without associated anaphylaxis.
- Trial name
- X-PAND (NCT00813748)
- Testing
- Xolair
- Where
- 7 sites in United States
- Volunteers
- 118 people
- Sponsor
- Genentech, Inc.
Asthma
A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.
The primary objective of this study is to determine the efficacy and safety of 4 doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily for four weeks in patients with asthma in comparison to…
- Trial name
- NCT01013753
- Testing
- Olodaterol (BI 1744) high, Olodaterol (BI 1744) medium, Olodaterol (BI 1744) very low
- Where
- 27 sites in Austria, Germany and 4 more
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Asthma
Safety and Efficacy of YHD001 in Asthma
The main objective is to evaluate the safety/tolerability and efficacy of YHD001 compared to singulair or placebo in patients (n=96) with partially controlled asthma.
- Trial name
- NCT01424124
- Testing
- YHD001 dose level 1, YHD001 dose level 2, Singulair
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Yuhan Corporation
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients
This study will involve the use of a new compound, GW642444 that is being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00463697
- Testing
- GW642444H (100mcg), GW642444M (25, 100 & 400 mcg)
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma, Uncontrolled Moderate to Severe
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to evaluate the efficacy and safety of Omalizumab produced by CinnaGen compared with Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland) in subjects with uncontrolled…
- Trial name
- NCT05813470
- Testing
- Omalizumab (CinnaGen), Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)
- Where
- 22 sites in Iran
- Volunteers
- 256 people
- Sponsor
- Cinnagen
Asthma
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in…
- Trial name
- NCT02141854
- Testing
- FS MDPI, Fp MDPI, Albuterol/salmeterol HFA MDI
- Where
- 154 sites in United States, Canada and 7 more
- Volunteers
- 882 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma
This is a Phase II, double-blind, placebo-controlled, cross-over trial to evaluate the efficacy of AIM-102 for the treatment of allergen-induced asthma.
- Trial name
- NCT01501942
- Testing
- AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide, Buffered Saline
- Where
- 2 sites in Canada
- Volunteers
- 11 people
- Sponsor
- AIM Therapeutics Inc.
Asthma
Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients
The purpose of this study is to assess the predictive ability of three asthma risk markers: the ratio of controller medication to total asthma medication, an albuterol only marker, and an oral corticosteroid use marker, as well…
- Trial name
- NCT01346852
- Testing
- Asthma treatment with an asthma-related medication and at least one asthma controller medication
- Volunteers
- 101,437 people
- Sponsor
- GlaxoSmithKline
Allergy
A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites
A phase III study to assess the efficacy and safety of sublingual immunotherapy with STALORAL dust mites solution compared with placebo for reduction of asthma symptoms.
- Trial name
- NCT00660452
- Testing
- Staloral
- Where
- China
- Volunteers
- 484 people
- Sponsor
- Stallergenes Greer
Asthma
No Resistance After Long Term Treatment SERETIDE
This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment…
- Trial name
- NCT00456313
- Testing
- FLIXOTIDE and SERETIDE
- Where
- 2 sites in Netherlands
- Sponsor
- GlaxoSmithKline
Asthma
TELICAST : Telithromycin in Acute Exacerbations of Asthma
Primary Objective: The primary objective is to evaluate the clinical efficacy of telithromycin versus placebo as a supplement to the usual standard of care during an acute exacerbation of asthma.
- Trial name
- NCT00273520
- Testing
- Telithromycin
- Sponsor
- Sanofi
Asthma
Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)
The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function, time to first asthma exacerbation, asthma symptoms, use of rescue medication, and quality of life in patients with…
- Trial name
- NCT00163423
- Testing
- Ciclesonide
- Where
- 51 sites in Austria, Canada and 3 more
- Volunteers
- 480 people
- Sponsor
- AstraZeneca
Severe Asthma
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
This study is an observational multicenter cross-sectional study. Planned study population consists of 5 000 adult patients with uncontrolled SA receiving treatment according to standard of care (except biologics).
- Trial name
- CORSAR (NCT06472310)
- Where
- 40 sites in Russia
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils.
- Trial name
- NCT02075255
- Testing
- Benralizumab
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Respiratory Tract Infections
Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels
Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their…
- Conditions
- Rhinitis, Allergic, Respiratory Tract Infections, Allergy, Allergic Asthma
- Trial name
- NCT04389034
- Testing
- Pollinex Quattro with tree- and grass pollen extracts and their mixtures
- Where
- Germany
- Volunteers
- 113 people
- Sponsor
- Allergy Therapeutics